Assembly Biosciences (ASMB) Cash from Financing Activities (2010 - 2026)

Assembly Biosciences' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $149000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 92.25% year-over-year to $149000.0; the TTM figure through Mar 2026 stood at $172.9 million (up 451.13% YoY), while the FY2025 annual figure was $174.7 million, up 493.12% from the prior year.
• Cash from Financing Activities was $149000.0 for Q1 2026 at Assembly Biosciences, down from $456000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $171.9 million in Q3 2025 to a low of $134000.0 in Q2 2023.
• Historically, Cash from Financing Activities has averaged $18.2 million across 5 years, with a median of $1.2 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 9194.03% in 2024, then tumbled 97.32% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $437000.0 in 2022, then jumped by 2003.43% to $9.2 million in 2023, then jumped by 84.89% to $17.0 million in 2024, then sank by 97.32% to $456000.0 in 2025, then slumped by 67.32% to $149000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $149000.0 (Q1 2026), $456000.0 (Q4 2025), and $171.9 million (Q3 2025), per Business Quant data.